The Good, the Bad, and the Best Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Good, the Bad, and the Best Jobs
Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

Pharmaceutical Technology
Volume 32, Issue 12, pp. 74-73

Worst aspects of jobs

"Lack of acknowledgment by management of my role."

"Constraints of compliance to change."

"Constant state of not knowing how long we will be employed."

"No rewards for going the extra mile," ... "or for discovery."

"Continuously changing internal requirements."

"High work load as many projects are pushed through the pipeline."

"Turnover" ... "and frequent reorganization."

"Waiting for results from universities."

"A dull and redundant work/repeat" and "shift work."

"No appreciation that we're running a global business and need global processes."

"Regulations, regulations, regulations."

"Lulls in the work cycle."

"Having to contract to people who think they know all the answers."

"Regular panic to meet customer deadlines."

"Management does not listen to or adapt new creative ideas."

"I'm stuck in a deadbeat town somewhere in Germany."

"No improvement in quality of products."

"Working across different time zones."

"Frustrations of failed experiments."

"It's hard to see how my daily activities are advancing the larger strategy."

"Slow computer systems," and "old, unreliable equipment."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here